Harmony Biosciences Holdings Inc. (HRMY) earns a Roarable Rating of B+ (Buy) with 80/100 RQD Confidence. High-quality cash engine (77% profit margin, 63% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.
As of 2026-11-01, Harmony Biosciences Holdings Inc. (NASDAQ: HRMY) is rated B+ (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 80/100 at a spot price of $38.59 (+0.23% 1D, market cap $2.25B). Pillar breakdown: Fundamental Cash Engine 20/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 18/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 19/20. Across 1016 tracked Health Care issuers, HRMY ranks #18 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), HRMY carries a Roarable B+ (80/100 RQD), trailing P/E of 14.2x, gross margin of 77.2%, and ROIC of 63.0%. By comparison, SDGR (Schrodinger Inc.) holds a D- grade (43/100 RQD, P/E N/A, ROIC -35.0%, cap $2.24B) and AGIO (Agios Pharmaceuticals Inc.) posts a D- grade (39/100 RQD, P/E N/A, ROIC -33.8%, cap $2.22B). Among the 5-stock peer group, AUPH leads on earnings multiple (8.0x) while HRMY leads on capital efficiency (63.0% ROIC).
Per HRMY's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001802665), Harmony Biosciences Holdings Inc. generated $868.5M in revenue (+21.5% YoY), $158.7M in net income, and $347.9M in free cash flow against $1.27B in total assets and $143.7M in total debt. Key quantitative strengths: Strong cash generator (77% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
SEC XBRL FY 2025 (10-K): 40.1% FCF Margin ($347.9M FCF) & 77.2% Gross Margin
SEC Form 4 / 13F Thermometer: 86% Net Buy • Cannibal Buyback (-3.20% YoY Shares)
Put hedging (50% put share) caps near-term gamma upside (-12 pts vs max)
Even with a 80/100 (B+) score, HRMY faces multiple-compression risk if 14.2x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
Broader market pullbacks can still drag down strong stocks in the short run.
Dilution & Margin Drag: Cannibal Buyback (-3.20% YoY Shares) — any gross margin slip below 74.7% triggers an automatic RQD downgrade.
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($39.76) or 200D SMA ($34.69) invalidates the momentum regime and cuts Target Base ($42.41) toward Bear Floor ($31.64).
Harmony Biosciences Holdings Inc. (HRMY) advanced +0.23% to $38.59, trading at 72% of its 52-week range ($25.9 – $43.49). High-quality cash engine (77% profit margin, 63% return on capital) with steady institutional support.
PTC Therapeutics (PTCT) delivered earnings and revenue surprises of +258.82% and +15.02%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
BioAge Labs, Inc. (BIOA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
GSK's Q3 earnings beat estimates as HIV, oncology and respiratory medicines drive revenue growth, while declining vaccine sales weigh on shares.
Harmony Biosciences (HRMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Harmony Biosciences remains under pressure since the company announced its CEO transition. Will an upcoming narcolepsy drug change that?
Bausch Health reports Q3 2026 results on Oct. 28, with $2.75 billion in expected sales. Explore key segment drivers and mixed earnings surprise history.
Tango Therapeutics stock falls 16.4% despite an 82% pancreatic cancer response rate and durable disease control, as investors weigh updated results and R&D cuts.
Dr. Reddy's Q2 earnings and revenues miss estimates as lower lenalidomide sales weigh on results despite growth in India and emerging markets.
Amid a Russell 2000 sell-off driven by rising rates, FIBK, EPAC, CCS, and HRMY show varied resilience, with analysts weighing risks against potential upside in each stock.
HRMY vs. ARGX: Which Stock Is the Better Value Option?
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +21.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on HRMY today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for HRMY. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Harmony Biosciences Holdings Inc. (HRMY) ranks #18 by composite RQD confidence (80/100, grade B+) and #239 by equity capitalization ($2.25B). Within this direct 5-issuer industry benchmark cohort, AUPH leads on earnings valuation at 8.0x trailing P/E, while HRMY leads on capital efficiency and profitability with 63.0% ROIC and 77.2% gross margin. HRMY currently leads its immediate peer cohort in composite quantitative strength at 80/100 (B+).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| HRMY
ACTIVE
Harmony Biosciences Holdings Inc. | B+ | 80/100 | 14.2x | 77.2% | 63.0% | +0.23% | $2.25B | Benchmark Subject |
| SDGR Schrodinger Inc. | D- | 43/100 | — | 55.7% | -35.0% | -2.85% | $2.24B | /sdgr-vs-hrmy → |
| AGIO Agios Pharmaceuticals Inc. | D- | 39/100 | — | 88.3% | -33.8% | -2.33% | $2.22B | /agio-vs-hrmy → |
| PRGO Perrigo Company plc | D- | 41/100 | — | 35.1% | -13.6% | -0.13% | $2.21B | /prgo-vs-hrmy → |
| AUPH Aurinia Pharmaceuticals Inc | B | 75/100 | 8.0x | 88.5% | 16.5% | -0.86% | $2.29B | /auph-vs-hrmy → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Harmony Biosciences Holdings Inc. (HRMY) reported GAAP revenue of $868.5M (+21.5% vs. FY2024 revenue of $714.7M , and +49.2% cumulative change since FY2023) , GAAP net income of $158.7M, operating cash flow of $348.2M, and free cash flow of $347.9M (+59.1% YoY). On the balance sheet, HRMY closed FY2025 with $1.27B in total assets against $143.7M in total debt (Altman Z-Score: 5.38, Piotroski F-Score: 9/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $868.5M | $158.7M | $348.2M | $347.9M | $1.27B | $143.7M |
| FY2024 (FY) | 2024-12-31 | $714.7M | $145.5M | $219.8M | $218.7M | $999.2M | $163.0M |
| FY2023 (FY) | 2023-12-31 | $582.0M | $128.9M | $219.4M | $219.4M | — | — |
As of 2026-11-01, Harmony Biosciences Holdings Inc. (NASDAQ: HRMY) is rated B+ (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 80/100 at a spot price of $38.59 (+0.23% 1D, market cap $2.25B). Pillar breakdown: Fundamental Cash Engine 20/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 18/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 19/20. Across 1016 tracked Health Care issuers, HRMY ranks #18 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), HRMY carries a Roarable B+ (80/100 RQD), trailing P/E of 14.2x, gross margin of 77.2%, and ROIC of 63.0%. By comparison, SDGR (Schrodinger Inc.) holds a D- grade (43/100 RQD, P/E N/A, ROIC -35.0%, cap $2.24B) and AGIO (Agios Pharmaceuticals Inc.) posts a D- grade (39/100 RQD, P/E N/A, ROIC -33.8%, cap $2.22B). Among the 5-stock peer group, AUPH leads on earnings multiple (8.0x) while HRMY leads on capital efficiency (63.0% ROIC).
Per HRMY's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001802665), Harmony Biosciences Holdings Inc. generated $868.5M in revenue (+21.5% YoY), $158.7M in net income, and $347.9M in free cash flow against $1.27B in total assets and $143.7M in total debt. Key quantitative strengths: Strong cash generator (77% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.
HRMY last traded at $38.59 (+0.23% on volume of 778,885 shares), positioning the stock -2.94% below its 50-day simple moving average ($39.76) and +11.24% above its 200-day simple moving average ($34.69). Across its 52-week range of $25.90 to $43.49, HRMY sits at the 72.1% percentile with a 14-day RSI of 51.1 (NEUTRAL RANGE) and an implied next-earnings move of ±8.9% ($35.16 to $42.02).
Why HRMY Stock advanced +0.23% Today — RQD Quant Desk Flash. High-quality cash engine (77% profit margin, 63% return on capital) with steady institutional support.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Paper Trading Arena account.